H.C. Wainwright maintains a Buy rating and $42 price target on Edgewise Therapeutics (EWTX) after the company announced additional CIRRUS-HCM Part B and C results evaluating a lower 25 mg fixed-dose of EDG-7500 in oHCM and nHCM participantsResults from the 25 mg dose demonstrated sustained clinical activity across key HCM disease markers, while maintaining a favorable safety profile, says the analyst, who sees the data reinforcing EDG-7500’s potential for differentiation.
Claim 70% Off TipRanks This Holiday Season
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on EWTX:
- Prolonged Safety Uncertainty and Eroding Differentiation Keep EDG-7500 at Hold
- Stifel says longer-term questions remain after Edgewise’s EDG-7500 update
- Edgewise Therapeutics rises 15.5%
- Truist remains bullish on Edgewise Therapeutics’ EDG-7500 opportunity
- Edgewise Therapeutics reports ‘positive’ updates from Phase 2 EDG-7500 trial